$17.46
-0.27(-1.52%)
Mkt Cap $628M
$3.04
$22.92
52-Week Range
At a Glance
AI-generatedBioAge Labs, Inc.
8-K
BioAge Labs, Inc. announced full year 2025 financial results with $9.0 million collaboration revenue, $73.9 million R&D expenses, $27.8 million G&A expenses, and $80.6 million net loss. Highlights include positive interim Phase 1 data for BGE-102 demonstrating 86% median hsCRP reduction and plans for Phase 2a trials, plus $132.3 million follow-on offering extending cash runway through 2029.$628M
Market Cap
$6M
Revenue
-$76M
Net Income
Employees62
Fundamentals
How The Business Makes Money
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001709941
ISINUS09077V1008
CUSIP09077V100
Phone510 806 1445
Address1445A South 50th Street, Emeryville, CA, 94804, US
SEC EDGAR